Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study
Authors:
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (1) , 200-203
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosisFertility and Sterility, 2020
- Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trialFertility and Sterility, 2020
- Current and Future Medical Therapies for AdenomyosisSeminars in Reproductive Medicine, 2020
- Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosisFertility and Sterility, 2018